Denison Mines Corp Ordinary Shares (Canada) vs Inovio Pharmaceuticals Inc — how do they compare? Denison Mines Corp Ordinary Shares (Canada) trades at $2.45 (market cap $2.14B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Denison Mines Corp Ordinary Shares (Canada) is far larger — about 19.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Denison Mines Corp Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Denison Mines Corp Ordinary Shares (Canada) for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DNN | INO | |
|---|---|---|
Market Cap | $2.14B | $112.19M |
Volume | 56,727,592 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $4.37 | $2.65 |
52-Week Low | $2.27 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $1.98B | $83.51M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Denison Mines is a uranium mining, development, and exploration company focused on Canada's Athabasca Basin. Its portfolio includes the Wheeler River project and interests in other uranium projects and processing facilities.
Read more on DNN →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →